Helping patients with bronchiectasiscystic fibrosisCOPDasthma

MCC Therapeutics, Inc. is developing novel therapeutics to improve mucociliary clearance (MCC) in people with various airway obstructive diseases.

The therapeutics are based on the discovery made by its founders at Stanford University, of potent synergism between cholinergic-adrenergic agonists

Technology

We advance the discovery of a novel, synergistic increase of airways mucociliary clearance by a combination of beta-adrenergic and cholinergic agonists.

Drug

MCCSA2- Inhaled Formoterol Fumarate and Methacholine Chloride

Clinical Trials

We conducted a Phase 1 single ascending dose study in human subjects at Stanford Medical Center.

News & Publications